Erasca, Inc.

Contributing Author

Recent Articles by Erasca, Inc.

Jun-02	Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 ERAS GlobeNewswire
May-29	Erasca to Present at Upcoming Investor Conferences in June ERAS GlobeNewswire
May-13	Erasca Reports First Quarter 2025 Business Updates and Financial Results ERAS GlobeNewswire
May-13	Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway ERAS GlobeNewswire
May-07	Erasca to Present at the Bank of America Securities Health Care Conference ERAS GlobeNewswire